Hims & Hers Q4 Revenue Jumps 28.4% to $617.8M, EPS Doubles; Buys Eucalyptus for $1.15B
Hims & Hers Health reported Q4 CY2025 revenue of $617.8 million, up 28.4% year-on-year, with GAAP EPS of $0.08, doubling analysts’ forecasts. The telehealth firm agreed to acquire Eucalyptus for up to $1.15 billion—$240 million upfront with the remainder via deferred and performance-based payments—funded through cash and operating cash flows and closing mid-2026.
1. Q4 Earnings Results
Hims & Hers Health posted Q4 CY2025 revenue of $617.8 million, up 28.4% year-on-year, driven by growth across dermatology and mental health segments. GAAP EPS reached $0.08, a 100% beat over analysts’ estimates, reflecting improving operating leverage.
2. Q1 Revenue Guidance
Management provided revenue guidance of $612.5 million for Q1 CY2026, approximately 5.6% below consensus forecasts, indicating a potential slowdown in sales momentum and heightening near-term investor scrutiny.
3. Eucalyptus Acquisition
The company agreed to acquire Eucalyptus for up to $1.15 billion, paying $240 million in cash at closing with the balance structured as deferred and performance-based payments. The deal is financed through existing cash and projected U.S. operating cash flows and is expected to close by mid-2026.